fair access for safe and timely generics act of 2017 or the fast generics act of 2017 this bill amends the federal food , drug , and cosmetic act to prohibit the license holder of a food and drug administration ( fda ) - approved drug or biological product from restricting availability of the medication for testing by a product developer seeking to develop a drug , generic drug , or biosimilar , including restricting availability with a risk evaluation and mitigation strategy ( rems ) .
upon request , the license holder of a medication that is not subject to a rems must provide a product developer with the medication for testing .
for a medication subject to a rems , a product developer must have fda authorization to obtain the medication before the license holder must provide it .
the fda may authorize a product developer to conduct testing and clinical trials with the medication .
a wholesaler or specialty distributor who receives a request from a product developer for a medication for testing may not disclose to the license holder the identity of the product developer .
the fda may prohibit or limit transfer of a medication to a product developer if the transfer poses an imminent hazard to public health .
license holders are not liable for claims arising from a product developer testing a medication .
the fda may waive the requirement that a medication use a single , shared system of elements to assure safe use with a comparable approved medication if the product developer is unable to finalize terms for a shared system with the license holder of the approved medication .